GRFE Stock Overview
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €9.64 |
52 Week High | €15.79 |
52 Week Low | €6.62 |
Beta | 0.67 |
1 Month Change | 11.52% |
3 Month Change | n/a |
1 Year Change | -16.73% |
3 Year Change | -58.81% |
5 Year Change | -59.07% |
Change since IPO | 0.068% |
Recent News & Updates
Recent updates
Shareholder Returns
GRFE | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | 1.9% | 0.5% |
1Y | -16.7% | -20.4% | 6.3% |
Return vs Industry: GRFE exceeded the UK Biotechs industry which returned -20.4% over the past year.
Return vs Market: GRFE underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
GRFE volatility | |
---|---|
GRFE Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: GRFE's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GRFE's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1909 | 23,000 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
GRFE fundamental statistics | |
---|---|
Market cap | €5.98b |
Earnings (TTM) | €189.00m |
Revenue (TTM) | €6.66b |
35.7x
P/E Ratio1.0x
P/S RatioIs GRFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GRFE income statement (TTM) | |
---|---|
Revenue | €6.66b |
Cost of Revenue | €4.09b |
Gross Profit | €2.56b |
Other Expenses | €2.37b |
Earnings | €189.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
Earnings per share (EPS) | 0.28 |
Gross Margin | 38.51% |
Net Profit Margin | 2.84% |
Debt/Equity Ratio | 140.3% |
How did GRFE perform over the long term?
See historical performance and comparison